Analysis Mereo BioPharma Group plc (0A9G)
5/26/2024
Analysis of Mereo BioPharma Group plc (0A9G)
Mereo BioPharma Group plc is showing some interesting price movements and technical indicators in the provided data. Here are some key points from the data:1. Price Movement: The closing prices have been fluctuating over the past few days, ranging from 2.998 to 4.145. This indicates some volatility in the stock.
2. RSI Indicator: The Relative Strength Index (RSI) values are mostly in the range of 40 to 70, indicating that the stock is neither overbought nor oversold. However, there are instances where the RSI has crossed 70, suggesting overbought conditions.
3. MACD Indicator: The Moving Average Convergence Divergence (MACD) values are positive for most days, indicating a bullish trend. The MACD histogram is also mostly positive, showing upward momentum.
4. Moving Averages: The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) values are close to each other, suggesting a stable trend.
Overall, based on the provided data, Mereo BioPharma Group plc seems to be experiencing some volatility but with a bullish bias in terms of technical indicators. Traders and investors may want to keep an eye on the RSI crossing 70 for potential overbought conditions and monitor the MACD for any changes in momentum.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 from the same quarter last year.
3. Looking at the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This shows a potential increase from the EPS of $6.59 reported for the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the upcoming quarters and fiscal years.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.33.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44.
Moving on to stock statistics, the company has a short ratio of 1.66, with 15.31 billion float shares and 94.31 million shares shorted. The average 10-day trading volume is 52.90 million shares, while the average 90-day trading volume is 62.82 million shares. The company has 15.33 billion shares outstanding, with 5.22% held by insiders and 57.56% held by institutions.
Valuation metrics show a PEG ratio of 26.21, forward PE of 26.21, trailing PE of 29.43, and an enterprise value of $2.95 trillion. The price to book ratio is 39.18, price to sales ratio is 7.62, enterprise to EBITDA ratio is 22.75, and enterprise to revenue ratio is 7.73. The market capitalization is $2.91 trillion.
The stock price summary includes a beta of 1.26, with a 50-day moving average of $173.69 and a 200-day moving average of $180.79. The 52-week low and high prices are $164.08 and $199.62 respectively, with a 52-week change of 8.25%.
Lastly, dividends and splits information shows a payout ratio of 14.93%, with a dividend date of May 16, 2024. The last split date was on August 31, 2020, with a 4-for-1 split factor. The forward annual dividend rate is $1, with a 5-year average dividend yield of 0.73% and a forward annual dividend yield of 0.53%. The trailing annual dividend rate is $0.97, with a trailing annual dividend yield of 0.51%.
Revenue estimate
Based on analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a generally positive outlook for the company, with expected growth in both quarterly and annual sales over the coming quarters and years.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It indicates a healthy growth trajectory for the company in the near future, albeit at a slightly slower pace than in the past.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions regarding the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is $191.57, which falls below the average and median forecast. Investors should consider these forecasts along with other factors when making investment decisions.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, such as net income and operating income, the trend in revenue growth has been positive.
3. The company seems to be effectively generating sales and increasing its top line, which is a good sign for its overall financial health and market position.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have also been on the rise, with the highest value in 2018 at $255,355,000,000.
5. Shareholders' equity has generally increased, with the highest value in 2018 at $107,147,000,000.
6. The company has been investing more in non-current assets over the years.
7. There is a fluctuating trend in current assets, possibly due to changes in short-term investments and receivables.
8. The company has been relying more on long-term debt to finance its operations.
9. Retained earnings have been positive throughout the years, indicating profitability and reinvestment in the business.
10. Overall, the company's financial position seems stable and has shown growth over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant cash outflows, mainly due to common stock repurchases and debt payments.
5. Investing activities also involve substantial cash flows, including acquisitions, capital expenditures, and investments.
6. The end cash position has been fluctuating, but overall, the company has maintained a healthy cash balance.
7. Stock-based compensation is a significant non-cash item that impacts the company's financials.
8. The company has been issuing and repurchasing common stock, as well as issuing long-term and short-term debt to manage its capital structure.
MACD of 0A9G
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
